Press Releases Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
32.48 ^USD	+2.23%		-0.18%	-21.09%

Apr. 24	Arvinas, Inc. Appoints Randy Teel as Chief Business Officer	CI
Apr. 15	H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer	Apr. 24	GL
Arvinas : 2024 Proxy Statement	Apr. 17	PU
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	Apr. 12	AQ
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024	Apr. 11	AQ
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer	Apr. 11	GL
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer	Mar. 18	GL
Arvinas to Participate in Upcoming Investor Conferences	Mar. 04	GL
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 27	GL
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 27	AQ
Arvinas Announces Chief Financial Officer Transition	Feb. 20	GL
Arvinas Announces Chief Financial Officer Transition	Feb. 20	AQ
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease	Feb. 20	GL
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer	Feb. 14	AQ
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer	Feb. 06	GL
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer	Feb. 06	AQ
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference	Feb. 01	GL
Arvinas Appoints Jared Freedberg as General Counsel	Jan. 16	GL
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib and Plans to Expand Vepdegestrant Development Program	Dec. 06	AQ
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program	Dec. 05	GL
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program	Dec. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arvinas, Inc.

Equities

ARVN

US04335A1051

Press Releases

Filters